Viatris takes control of Pacira, guiding to $90–100m of sales by year-end
The generics and brands group has taken full ownership of the pain-focused drugmaker, and says the business should add up to $100 million in revenue before the calendar year closes.
17 Nov 2026 · Viatris Inc VTRS · Company news
Viatris has taken full ownership of Pacira BioSciences, a US company that focuses on pain treatments that do not rely on opioids. The group announced on 17 November 2026 that the transaction is done, and that it expects the newly acquired business to bring in $90–100 million of revenue between that date and 31 December.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Viatris Inc ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
More Deals & M&AAll →
Deals & M&A
UL Solutions to acquire supply chain software firm Worldly in roughly $350M deal
17 Nov 2026 · UL Solutions Inc. ULS · Company news
Deals & M&A
Gedeon Richter to acquire Mayne Pharma in AUD 604 million cash deal
16 Nov 2026 · Gedeon Richter · Company news
Deals & M&A
Aytu BioPharma to be acquired by Rosemont for about $56M as EXXUA sales grow
16 Nov 2026 · Aytu Biopharma, Inc AYTU · Company news
Deals & M&A
Merck KGaA to acquire Rapid Micro Biosystems in $0.75-per-share cash tender offer
16 Nov 2026 · Rapid Micro Biosystems, Inc. RPID · Company news
Deals & M&A
ENDRA reports Q3 net loss of $1.5m as Noble Africa merger awaits closing conditions
16 Nov 2026 · ENDRA Life Sciences Inc. NDRA · Company news
Deals & M&A
Jasper Therapeutics completes IgAN cohort enrolment as Kira deal closes and cash reaches $135.3M
16 Nov 2026 · Jasper Therapeutics, Inc. JSPR · Company news